The digital health landscape is evolving rapidly, and regulatory frameworks are working to keep pace with emerging software‑driven innovations. The FDA’s TEMPO Pilot Program—Technology‑Enabled Meaningful Patient Outcomes—represents one of the most significant recent attempts to modernize digital health evidence and market access pathways. It aims to streamline certain premarket requirements for a select group of Software‑as‑a‑Medical‑Device (SaMD) products while reinforcing safeguards around safety and real‑world performance.
While the TEMPO Pilot Program has generated a great deal of excitement, enthusiasm alone is not a substitute for strategic evaluation. The program is intentionally small in scale, tightly scoped, and paired with substantial conditions that must be fully understood before a manufacturer considers pursuing it. The most important among these is that the TEMPO Pilot Program is inseparably linked to CMS’ ACCESS (Accelerating Clinical Evidence) Model.
The goal of this article is to provide clear, reasoned guidance on how to assess the TEMPO Pilot Program, when participation may be advantageous, when it may present hidden risks, and why traditional pathways may remain the strongest option for many emerging digital health technologies.
Understanding the Structural Link Between TEMPO and ACCESS
A critical point is often overlooked in early discussions about the TEMPO Pilot Program: participation requires prior acceptance into the CMS ACCESS Model. The FDA and CMS designed these programs to function together. TEMPO offers potential flexibility in premarket evidence, while ACCESS governs reimbursement, evaluation, and long‑term oversight. TEMPO is not a shortcut to FDA clearance, nor a standalone option for early market entry.
If a technology does not align with the ACCESS Model, it is automatically excluded from the TEMPO Pilot Program. In this sense, ACCESS—not TEMPO—is the defining factor. Understanding whether a product meets ACCESS criteria is the first step in determining whether TEMPO is appropriate.
ACCESS Focuses on Early‑Stage Chronic Disease, Not All Patient Needs
The ACCESS Model is specifically designed around outcomes for early‑stage chronic disease management. CMS selected endpoints that are:
- Measurable on a frequent basis
- Applicable to a vast proportion of Medicare beneficiaries
- Predictive of long‑term risk reduction
- Useful in case‑control evaluation models
These endpoints currently include:
- Blood pressure control
- Weight maintenance
- Glucose regulation
- Similar metrics associated with metabolic and cardiovascular risk factors
This is a decisive point for manufacturers evaluating the TEMPO Pilot Program. If a SaMD is designed to address a later‑stage condition, for example, heart failure decompensation, cardiopulmonary instability, or post‑discharge deteriorations, clinical value does not fit the ACCESS definition. This misalignment is not due to a lack of value. Rather, the model’s current endpoints focus on broad, population‑level, upstream risk reduction.
A digital tool that prevents hospitalizations, identifies early hemodynamic instability, or offers a noninvasive alternative to implantable devices may have exceptional clinical value. But if these benefits are not among ACCESS’ required endpoints, the technology is not positioned to succeed within the TEMPO Pilot Program.
A Limited Pilot: ACCESS Will Accept Only 10 Technologies Per Cycle
Another critical factor is program capacity. CMS has indicated that only 10 technologies will be selected per ACCESS cycle. Competition will be extremely high, especially among:
- Diabetes management platforms
- Hypertension monitoring tools
- Lifestyle modification systems
- Integrated platforms used by millions of beneficiaries
Technologies addressing smaller or more advanced populations, even when clinically meaningful, are structurally disadvantaged in this selection process.
Manufacturers must evaluate the likelihood of selection realistically, based not on clinical merit alone but on CMS’ explicit focus on population‑wide impact.
Reimbursement Under ACCESS May Cap Future Market Potential
The reimbursement structure within ACCESS is one of the most consequential considerations for manufacturers evaluating the TEMPO Pilot Program. For technologies that provide incremental lifestyle or metabolic support, this may be acceptable.
For higher‑value digital health products, including those that:
- Provide early detection of clinical deterioration
- Compete with expensive implantable devices
- Deliver actionable physiologic insights
- Operate under service‑intensive monitoring models
…the ACCESS reimbursement ceiling may significantly limit long‑term commercial viability.
Manufacturers must consider whether ACCESS participation, and therefore engagement with the TEMPO Pilot Program, would anchor their reimbursement permanently at levels that do not reflect the product’s true clinical or economic value.
Design Modifications May Be Required to Fit ACCESS Endpoints
To succeed in ACCESS, manufacturers may need to modify their technology to align it with required endpoints. In practical terms, this may mean:
- Adding workflows for weight measurement
- Incorporating blood pressure inputs
- Collecting additional patient‑reported metrics
- Altering the measurement protocol
- Expanding the intended use population
For some technologies, these modifications may be relatively easy. For others, particularly those built around highly novel physiologic insights, such changes may:
- Dilute the product’s differentiation
- Increase development burden
- Complicate FDA submissions
- Shift focus away from the device’s strongest claims
- Delay time to market
Manufacturers must weigh these tradeoffs carefully before pursuing the TEMPO Pilot Program.
When the Traditional FDA Pathway Is the Stronger Strategic Choice
For many digital health technologies, especially those targeting later‑stage chronic disease, acute deterioration, hospitalization prevention, or high‑risk populations, a traditional FDA submission combined with a targeted evidence and reimbursement strategy will remain the most advantageous option.
A pathway built on:
- A well‑designed clinical trial aligned with intended use
- Clear demonstration of meaningful improvement
- Strong real‑world evidence collection
- Scalable payer engagement
- Reimbursement strategies that reflect true value
…may offer more control, fewer constraints, and far better long‑term financial viability than ACCESS and the TEMPO Pilot Program.
TEMPO offers certain accelerations, but those accelerations only matter when the underlying reimbursement environment supports long‑term growth.
Future ACCESS Tracks May Expand Program Relevance
CMS has indicated potential future expansions of the ACCESS Model, including the possibility of adding conditions and endpoints that reflect later‑stage disease or hospitalization‑related outcomes.
If ACCESS grows to include endpoints such as hospitalization risk reduction or prevention of acute deterioration, the relevance of the TEMPO Pilot Program could expand significantly.
However, manufacturers should build strategy around the program as it exists today, not as it may evolve in the future.
Conclusion
The TEMPO Pilot Program represents an important step in the evolution of digital health regulation. It reflects a clear commitment to enabling responsible innovation, particularly in early‑stage chronic disease management.
Yet, participation must be evaluated with rigor. TEMPO’s value depends entirely on ACCESS alignment, and ACCESS is intentionally limited in scope. For many technologies—particularly those delivering high‑value insights for later‑stage conditions—traditional FDA pathways paired with strategic evidence development will continue to offer the clearest, strongest, and most commercially viable route to market.
The TEMPO Pilot Program is an opportunity, but only for technologies whose clinical model, evidence needs, and value proposition align precisely with what ACCESS is designed to evaluate.
Frequently Asked Questions
What is the primary purpose of the TEMPO Pilot Program?
The TEMPO Pilot Program is designed to streamline FDA evidence requirements for a small set of digital health technologies participating in CMS’ ACCESS Model.
Does TEMPO replace the 510(k) or De Novo pathway?
No. TEMPO modifies certain evidence expectations but does not replace standard FDA pathways.
Is the TEMPO Pilot Program appropriate for technologies preventing hospitalizations?
Not today. These outcomes are not aligned with current ACCESS endpoints.
Do manufacturers need to modify their device to fit ACCESS criteria?
In many cases, yes. The required endpoints may necessitate workflow or design adjustments.
Can participation in the TEMPO Pilot Program limit long‑term pricing?
It can. ACCESS reimbursement may anchor future pricing expectations.
